Affiliation:
1. From the Departments of Radiotherapy and Hematology, Leiden University Medical Center, Leiden; Departments of Hematology and Radiotherapy, Daniël den Hoed Cancer Center, Rotterdam; Department of Radiotherapy, Netherlands Cancer Institute, Amsterdam; Department of Radiotherapy, Radiotherapeutisch Instituut Limburg, Heerlen; Department of Hematology, University Medical Center Nijmegen, Nijmegen, the Netherlands; Departments of Medical Oncology, Radiotherapy, Pathology, and Biostatistics and Epidemiology,...
Abstract
Purpose In early-stage Hodgkin's lymphoma (HL), subtotal nodal irradiation (STNI) and combined chemotherapy/radiotherapy produce high disease control rates but also considerable late toxicity. The aim of this study was to reduce this toxicity using a combination of low-intensity chemotherapy and involved-field radiotherapy (IF-RT) without jeopardizing disease control. Patients and Methods Patients with stage I or II HL were stratified into two groups, favorable and unfavorable, based on the following four prognostic factors: age, symptoms, number of involved areas, and mediastinal-thoracic ratio. The experimental therapy consisted of six cycles of epirubicin, bleomycin, vinblastine, and prednisone (EBVP) followed by IF-RT. It was randomly compared, in favorable patients, to STNI and, in unfavorable patients, to six cycles of mechlorethamine, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (MOPP/ABV hybrid) and IF-RT. Results Median follow-up time of the 722 patients included was 9 years. In 333 favorable patients, the 10-year event-free survival rates (EFS) were 88% in the EBVP arm and 78% in the STNI arm (P = .0113), with similar 10-year overall survival (OS) rates (92% v 92%, respectively; P = .79). In 389 unfavorable patients, the 10-year EFS rate was 88% in the MOPP/ABV arm compared with 68% in the EBVP arm (P < .001), leading to 10-year OS rates of 87% and 79%, respectively (P = .0175). Conclusion A treatment strategy for early-stage HL based on prognostic factors leads to high OS rates in both favorable and unfavorable patients. In favorable patients, the combination of EBVP and IF-RT can replace STNI as standard treatment. In unfavorable patients, EBVP is significantly less efficient than MOPP/ABV.
Publisher
American Society of Clinical Oncology (ASCO)
Reference39 articles.
1. Henry-Amar M, Somers R: Survival outcome after Hodgkin's disease: A report from the international data base on Hodgkin's disease. Semin Oncol 17:758,1990-768,
2. Long-Term Cause-Specific Mortality of Patients Treated for Hodgkin’s Disease
3. Bergsagel DE, Alison RE, Bean HA, et al: Results of treating Hodgkin's disease without a policy of laparotomy staging. Cancer Treat Rep 66:717,1982-731,
4. Long-term toxicity of early stages of Hodgkin's disease therapy: The EORTC experience
5. Causes of death after therapy for early stage Hodgkin's disease entered on EORTC protocols
Cited by
198 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献